Latest news with #JoeJimenez
Yahoo
22-05-2025
- Sport
- Yahoo
Braves insider: Slow start to season won't stop Atlanta from adding ‘big names' at trade deadline
It's been an uphill climb for the Atlanta Braves this season. After starting 0-7, they are currently at .500 with a 24-24 record, but that won't stop them from adding at the trade deadline, according to a Braves insider. Heading into the season, they knew they would be without ace Spencer Strider (internal brace surgery recovery) and former MVP Ronald Acuna Jr. (torn ACL recovery), but the hits kept coming. Advertisement The Braves signed outfielder Jurickson Profar to a three-year, $42 million contract following an All-Star season with the San Diego Padres and expected him to fill Acuna's void until he returned. But after playing just four games, he was suspended 80 games after testing positive for a PED. He's eligible to return in late June but is prohibited from postseason play. They also potentially lost All-Star starter Reynaldo Lopez (right shoulder inflammation) and top reliever Joe Jimenez (left knee cartilage damage) for the season. Strider returned to the rotation on April 16, only to go back on the IL due to a right hamstring strain. He missed another month before being reinstated May 19. Despite their struggles, Braves reporter Grant McCauley for 92.9 The Game believes the franchise will be active at the trade deadline because they weren't able to accomplish their offseason goals. Advertisement 'In no version of the script would I say, 'Well, the Braves looked at their pitching staff and thought they didn't need anything,'' McCauley told the 'Foul Territory' podcast. 'I think they would've liked to have gotten another high-leverage reliever, which was only made worse when Joe Jimenez could be out for the year. And I think they would've liked to have added somebody to fortify the rotation and really give them that standout group. I think those are still areas that they're going to go out and shop for.' McAuley added that the Braves won't be hampered by payroll, making them 'a very intriguing team out there lurking for some big names.' 'I think that they are poised to do something at the trade deadline and I've heard Alex Anthopoulos talk about it, the math for them, how they look at the luxury tax and when you get to the trade deadline, you're really only talking about having to pay for a third of that player's salary for the year,' said McAuley. Advertisement Currently, the Braves are six games behind the Philadelphia Phillies for the NL East lead and are four out of the last Wild Card spot. Related Headlines
Yahoo
25-03-2025
- Health
- Yahoo
Tempero Bio gets $70M to advance substance abuse treatment
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Tempero Bio, a biotechnology company based in Oakland, California, has secured $70 million to advance a drug it's developing into mid-stage testing for cocaine and alcohol use disorders. The Series B round, announced by Tempero Monday, will support two Phase 2 trials of the drug, called TMP-301. The biotech will also use the funds to prepare for late-stage studies as well as to explore additional indications and formulations. The round was led by investor 8VC, and also involved Khosla Ventures and Aditum Bio, among others. A relatively new investor in biotech, Aditum previously backed Versanis Bio, an obesity drug developer acquired by Eli Lilly in 2023. The investment firm is run by former Novartis CEO Joe Jimenez and Mark Fishman, formerly head of Novartis Institutes for BioMedical Research. Aditum launched Tempero in 2020 via a partnership with the pharmaceutical company Sosei Heptares, now called Nxera Pharma. Nxera licensed TMP-301 to Tempero in exchange for an upfront payment and equity stake, while Aditum put up Tempero's initial funding. According to Tempero, TMP-301 is designed to 'address neurobiological basis of addiction' by reducing excessive signaling via a neurotransmitter called glutamate. More specifically, TMP-301 modulates the metabotropic glutamate receptor 5, which is involved in central nervous system function. Tempero said the drug showed potential in preclinical models of opiate, alcohol and cocaine use disorders. It has been tested in about 80 healthy individuals as part of a Phase 1 study. 'Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year. We urgently need more effective treatments to help patients and families with these diseases,' Tempero CEO Ricardo Dolmetsch said in a statement. While psychiatry drugs have regained investor and drugmaker attention in recent years, the pipeline of novel treatments for substance use disorders remains thin. One new area of promise is the GLP-1 drugs currently used for diabetes and weight loss. Their makers are now studying their effects in curbing alcohol use. Recommended Reading New Biogen CEO seeks to 'redefine' company after challenging year Sign in to access your portfolio
